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Abstract
Background: Canine keratoconjunctivitis sicca (cKCS) is an inflammatory eye condition related to a deficiency in the
tear aqueous fraction. Etiopathogenesis of such disease is substantially multifactorial, combining the individual genetic
background with environmental factors that contribute to the process of immunological tolerance disruption and, as a
consequence, to the emergence of autoimmunity disease. In this occurrence, it is of relevance the role of the
physiological immune-dysregulation that results in immune-mediated processes at the basis of cKCS. Current
therapies for this ocular disease rely on immunosuppressive treatments. Clinical response to treatment frequently
varies from poor to good, depending on the clinical-pathological status of eyes at diagnosis and on individual
response to therapy. In the light of the variability of clinical response to therapies, we evaluated the use of an anti-
inflammatory/antioxidant nutraceutical diet with potential immune-modulating activity as a therapeutical adjuvant in
cKCS pharmacological treatment. Such combination was administered to a cohort of dogs affected by cKCS in which
the only immunosuppressive treatment resulted poorly responsive or ineffective in controlling the ocular symptoms.
Results: Fifty dogs of different breeds affected by immune-mediated cKCS were equally distributed and randomly
assigned to receive either a standard diet (control, n = 25) or the nutraceutical diet (treatment group, n = 25) both
combined with standard immunosuppressive therapy over a 60 days period. An overall significant improvement
of all clinical parameters (tear production, conjunctival inflammation, corneal keratinization, corneal pigment
density and mucus discharge) and the lack of food-related adverse reactions were observed in the treatment
group (p < 0.0001).
Conclusions: Our results showed that the association of traditional immune-suppressive therapy with the antioxidant/
anti-inflammatory properties of the nutraceutical diet resulted in a significant amelioration of clinical signs and
symptoms in cKCS. The beneficial effects, likely due to the presence of supplemented nutraceuticals in the diet,
appeared to specifically reduce the immune-mediated ocular symptoms in those cKCS-affected dogs that were poorly
responsive or unresponsive to classical immunosuppressive drugs. These data suggest that metabolic changes could
affect the immune response orchestration in a model of immune-mediated ocular disease, as represented by cKCS.
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Background
Keratoconjunctivitis sicca, also defined as “dry eye disease”
or Sjögren’s syndrome in human [1], is a tear film disorder
which causes inter-palpebral ocular surface damage and is
associated with ocular discomfort [2, 3] both in humans
and dogs [4, 5]. Canine keratoconjunctivitis sicca (cKCS)
is an inflammatory eye condition which affects both cor-
nea and conjunctiva and that is related to a deficiency in
tear aqueous fraction [6]. The prevalence of such disease
is estimated in about 4% when considering Schirmer
test I (STT) values < 10 mm/min [7] reaching the 64%
in male crossbred dogs between six to nine years of age
[8]. Moreover, it is often an under-recognized and/or a
sub-clinical condition [9] which, in some breeds, is pre-
ceded by an immune-mediated destruction of lachrymal
glands [10, 11].
In this regard, the immune-mediated mechanisms of
cKCS or of human, like the Sjögren’s syndrome [1] in-
duction are not clearly defined. Etiopathogenesis of such
disease is substantially multifactorial, combining the in-
dividual genetic background with environmental factors
that contribute to the process of immunological toler-
ance disruption and, as consequence, to the autoimmun-
ity processes [12–14]. It is of relevance the role of the
physiologic immune-dysregulation that results in the
autoimmune process of cKCS and Sjögren’s syndrome
[12–15]. Notably, the T and B cell infiltration, the recruit-
ment of dendritic cells, the up regulation of those mole-
cules fostering the antigen presentation as well as the
increased secretion of pro-inflammatory cytokines, such as
interferon (IFN)-γ [16], in ocular tissues have been demon-
strated to contribute to the inflammatory alterations of the
lachrymal gland [17–19]. This process usually results in
mucopurulent-like eye discharge, conjunctival hyperemia,
keratitis, corneal pigmentation, neovascularization and
blepharospasm in cKCS [20, 21].
Current therapies for this ocular disease rely on
immune-suppressive treatments, represented by Cyclo-
sporine A [22], glucorticoid [21], tacrolimus [23] and
artificial tears in order to recover an adequate eye’s lu-
brication [24]. Nevertheless, recognized complementary
or alternative therapeutical approaches are represented
by the cholinergic agents (pilocarpine) [25] and the sur-
gical treatments (punctal occlusion, tarsorrhaphy, con-
junctival flaps, contact lenses, superficial keratectomy, as
well as parotid duct transposition) [26]. Clinical response
to treatment frequently varies from poor to good, de-
pending on the clinical-pathological status of eyes at
diagnosis and on individual response to therapy [13].
Among other causes of cKCS traumas [27], congenital
causes [28], distemper [29], radiation therapy [30, 31],
neurological deficit [32], diabetes mellitus [33] and un-
corrected prolapse of the nictitans gland [34] are of note.
Intriguingly, majority of these aspects could correlate
and contribute to both the determinism and exacerba-
tion of inflammatory condition in ocular tissue.
In the light of the variability of clinical response to clas-
sical therapies, it could be useful the use of therapeutical
adjuvants in cKCS management to improve the response
to pharmacological treatment. Thus, we evaluated a com-
bined therapeutical approach based on the classical drug
administration and the use of an anti-inflammatory/anti-
oxidant diet with potential immune-modulating activity.
Such combination was administered to a cohort of cKCS
dogs in which the only immune-suppressive treatment
resulted poorly responsive or ineffective to control the
ocular symptoms.
The nutraceutical diet used in this clinical evaluation
consisted in a commercial mixed formula based on fish
proteins, rice carbohydrates (whose carbohydrates per-
centage ranges from 75 up to 80, starch 65 to 70% with
a beta-glucans quote of less than 0.1%), Cucumis melo,
Ascophyllum nodosum, Astaxanthin (from Hematococcus
pluvialis), Aloe vera, Carica papaya, Punica granatum,
Camellia sinensis, Polygonum cuspidatum, Curcuma
longa, Piper nigrum, zinc and a Omega3/6 ratio of 1:0.8),
which already provided significant immunomodulating
results, decreasing type 1 helper T lymphocyte (Th1)
cells and increasing T regulatory (Treg) cells, in dogs
affected by Leishmania infantum [35].
Cucumis melo (melon) shares some anti-oxidant and
anti-inflammatory properties that involve the superoxide/
peroxynitrite clearance and the modulation of macropha-
gal interleukin-10 production [36], while the immune-
modulating activity is exerted by the induction of type 1
helper T lymphocyte (Th1) polarization [37].
The Ascophyllum nodosum activity is related to the
presence of a sulfated-polysaccharide, ascophyllan, able
to induce nitric oxide, tumor necrosis factor (TNF)-α
and granulocyte colony-stimulating factor (GM-CSF) se-
cretion in macrophages [38]. Astaxanthin, an orange-
pinkish carotenoid, is known to act on polyunsaturated
fatty acids oxidation [39], inflammatory responses modu-
lation, and to promote eye’s health in humans and animals
[40]. This carotenoid induces lymphoblastogenesis and
lymphocyte cytotoxicity in mice [41] as well as T-cell and
B lymphocyte proliferation and natural killer cytotoxicity
in humans [42]. Reduced production of Interleukin (IL)-
1β, IL-6, TNF-α and IL-10 has been observed in vitro after
the addition of Aloe vera (aloe) extracts to the culture of
corneal cells [43]. The anti-inflammatory effect of Carica
papaya (papaya) is related to an increase of regulatory T
cells and a reduction of IFN-γ+ CD4+ T cells [44]. Reduc-
tion of IL-2 and IL-4 and enhancement of IL-12, inter-
feron (IFN)-γ and TNF-α have been observed in blood
mononuclear cells [45]. The seed oil and juice of Punica
granatum (pomegranate) contains some flavonoids and
anthocyanidins (delphinidin, cyaniding and pelargonidin)
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with an antioxidant activity greater than green tea extract
[46, 47]. Its antioxidant action is related to free radical
scavenging by anthocyanidins [46] and to metal ions che-
lation [48]. A protective effects of Punica granatum on
cardiovascular system has been correlated to angiotensin
converting enzyme inhibition, blood pressure decrease
[49] and endothelial nitric oxide syntase production [50].
Punica granatum also has been shown to inhibit cyclo-
oxygenase, lipooxygenase [51] and IL-1β, modulate
matrix metallo-proteinases in osteoarthritis, prevent
collagen degradation [52], inhibit the p38-mitogen-
activated protein kinase pathway and nuclear factor
kappa (NF-kB) light-chain-enhancer in B cells [53, 54],
and decrease malondialdehyde, TNF-α, IL-1β and IL-6
[55, 56].
The antioxidant effects of Camellia sinensis (green
tea) are exerted through radicals scavenging and lipid-
peroxidation inhibition [57] by flavonoids (catechin, epi-
catechin, epigallocatechin and gallate esters) [58]. In this
context, epigallocatechin-3-gallate is known to inhibit
UVB-mediated erythema, hydrogen peroxide production,
leukocyte infiltration [59], matrix metallo-proteinases
[60, 61], neutrophil chemotaxis [62], degradation of car-
tilage [63], TNF-α expression [64], neutrophil-mediated
angiogenesis [62] and reduce the cyclooxygenase-2 and
neutral endopeptidase activity [65]. Polygonum cuspida-
tum (japanese knotweed), a natural source of resveratrol,
is endowed with anti-inflammatory and antioxidant ac-
tivities [66, 67]. Resveratrol has been shown to directly
act on TANK-binding kinase 1, an integral component
in chronic inflammatory diseases [68], and on arteries by
activating the nitric oxide/soluble guanylyl cyclase path-
way [69]. Its anti-inflammatory effect is supposed to be
regulated by estrogen receptor-α [70]. Moreover, certain
resveratrol dimers (parthenocissin A, quadrangularin A
and pallidol) exert free radical quenching and, select-
ively, single oxygen scavenging activity [71]. Curcuma
longa (curcuma) induces powerful free radicals scavenging
effect and anti-inflammatory activity [72, 73]. Curcumin,
one of the constituents of such plant, reduces leukocyte
adhesion and superoxide production, stimulates spontan-
eous apoptosis and inhibits IL-8 [74].
Moreover, a down regulation of Th1 cytokine response
and of macrophagal nitric oxide production has also
been observed [75]. The anti-inflammatory effect of cur-
cumin involves the inhibition of NF-kB in activated B
cells and the down-regulation of TNF-α and IL-6 [73] as
well as the up-regulation of nuclear factor erythroid 2
activity [76], whose downstream proteins are involved in
the protection mechanisms against oxidative stress [77].
Piper nigrum (pepper) commonly used in the treatment
of flu, cold, rheumatism, pain, muscular aches, chills, ex-
haustion, fevers, is used as a useful nerve tonic also able
to increase blood circulation and saliva production as
well as to stimulate appetite and peristalsis [78]. It is also
known to enhance the effectiveness and bioavailability of
curcumin [79] by acting on membrane lipid dynamics in
reason of the apolar nature of piperine, the main bio-
active compound of Piper nigrum. Piperine has been
shown to promote conformational changes of intestine
enzymes [80] and significantly inhibit the expression of
major histocompatibility complex class II, CD40 and
CD86 in bone-marrow-derived dendritic cells as well as
the production of TNF-α and IL-12 by the same cells
[81]. In addition, piperine was proven to attenuate in-
flammatory processes by partially acting on pituitary ad-
renal axis [82], reduce high-fat diet-induced oxidative
stress [83, 84] and enhance pancreatic activity [85]. The
deficiency of zinc affects both innate and adaptive
immunity [86]. This element is crucial for the balance
between the different T-cell subsets and its deficiency
was shown to decrease the production of Th1 cytokines
(IFN-γ, IL-2 and TNF-α), whereas the Th2 response (IL-
4, IL-6 and IL-10) is affected in a lesser extent [87].
While acute zinc deficiency seems to correlate with the
decrease in innate and adaptive immunity, its chronic
deficiency is known to increase pro-inflammatory cyto-
kines (IL-1β, IL-6 and TNF-α) production influencing
the outcome of several inflammatory diseases [88].
An optimal balance of the omega Omega 3/6 fatty
acids ratio represents a fundamental requirement for
tissue homeostasis recovering during inflammatory re-
sponses. The polyunsaturated fatty acids, usually found
in fish oil (i.e., eicosapentaenoic acid and docosahexae-
noic acids), are known to decrease proinflammatory
cytokine production and to inhibit natural killer cell activ-
ity [89]. The gamma-linolenic acid has been demonstrated
to exert an anti-inflammatory activity by suppressing
IL-1β and TNF-α secretion by monocytes [90]. Add-
itionally, eicosapentaenoic supplementation might fos-
ter the anti-inflammatory activity of gamma-linolenic
acid by decreasing the synthesis of arachidonic acid
and prostaglandin E2 [91].
Here, we evaluated the use of a commercially avail-
able nutraceutical diet as a therapeutical adjuvant in
cKCS-affected dogs that were unresponsive to standard
pharmacological therapies.
Methods
Experimental design, dogs and diets
This evaluation was designed as a randomized, placebo-
controlled clinical one. Fifty client-owned dogs (19 fe-
males and 31 males) aged 6.5 ± 0.7 years [mean ± Standard
Error of Mean] of different breeds (one poodle, two dachs-
hund long hair, four dachshund smooth coat, four west
highland white terrier, two yorkshire terrier, four maltese,
one bulldog, two chinese crested dog, two chinese pug,
eight shih tzu, four german shepherd, 10 mixed breed,
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two chow chow, two cocker, two english setter) were
enrolled in this evaluation. All dogs were previously
evaluated by an Italian Animal Health Foundation cer-
tified panelist (Dr D. Giretto) to confirm the diagnosis
of immune-mediated KCS. Inclusion criteria were the
presence of blepharospasm, conjunctival inflammation,
corneal keratinization, corneal pigmentation density,
neovascularization, mucus discharge and a STT value
< 10 mm/min. Exclusion criteria were the presence of
correlated systemic diseases, neurological disease, trau-
matic and toxic keratoconjunctivitis, in order to better
evaluate the clinical response to the immune-mediated
cKCS, or general symptoms of intolerance/allergy to
ingredients of the nutraceutical diet tested in this clinical
evaluation. Moreover subjects affected by neurological
cKCS were excluded.
Dogs were randomly and equally divided into two
groups: 25 dogs fed a standard diet (SD group), as control
group, and 25 fed an antioxidant/anti-inflammatory nutra-
ceutical diet (ND group), as experimental group. Male and
female dogs were equally represented in both groups. Re-
gardless the type of diet, all dogs were treated over a
60 days period as follows: [0,03% Tacrolimus collyrium di-
luted into a benzalkonium chloride and methyl cellulose
solution (Lacrimart, Fedel Farma S.r.l., Chieti, Italy) BID
and 0,2% Hyalistil eye drops (artificial tears, S.I.F.I. S.p.A.
Aci S. Antonio, Catania, Italy) five times a day] ([http://
eng.forza10.com/immuno-active-755-2.html]).
The recommendations of the ARRIVE guidelines in
animal research were consulted and considered [92].
In Table 1, we reported the background data of the
dogs belonging to both groups along with their scores
before starting the evaluation.
Both diets completely fulfil the recommendations for
proteins, carbohydrates and fats in order to obtain a
complete food for a daily ration in dog, as reported in
Nutritional Guidelines for complete and complementary
pet food for cats and dogs by The European Pet Food
Industry Federation. Foods were in the form of kibbles
industrially produced with extrusion technique. ND and
SD foods reported similar analytical composition in
nutrients (24% of crude protein, 12% of crude oils and
fats, 3.7%, of crude fiber 5% of crude ash, 9% of mois-
ture). Both diets had analogue recipes and included the
same macro and micro nutrients including vitamins,
trace elements and minerals. The two foods differed
mainly from the presence of botanicals in ND food. ND
food was composed by two mixed components: kibbles,
included in the ideal percentage of 93-94% in weight,
and cold-pressed tablets at the 6-7% in weight of
complete food (European patent n. EP 2526781). Tablets
were composed by 60-80% of protein hydrolyzed (fish
and vegetable ones), 20-40% of minerals used as glidants
and were added by therapeutical substances (Ascophyl-
lum nodosum, Cucumis melo, Carica papaya, Aloe vera,
Astaxanthin from Haematococcus pluvialis, Curcuma
longa, Camellia sinensis, Punica granatum, Piper
nigrum, Poligonum spp, Echinacea purpurea, Grifola
frondosa, Glycine max, Omega 3 and Omega 6 un-
saturated fatty acids from fish, as 1.60% and 1.25% of oil
respectively).
The pet food used in SD group did not contain the
above-mentioned active substances.
ND and SD dietary administration were administrated
following a daily table recommendation (Table 2) and
carefully adjusted during the trial to provide similar cal-
oric animal food intake and to satisfy the nutritional re-
quirement of adult dogs. In order to avoid any
deficiency, the energy value of both complete food was
calculated using the expression suggested by Nutritional
Guidelines for Complete and Complementary Pet Food
for Cats and Dogs and Nutrient requirements of dogs
and cats, National research council of the National acad-
emies, (% crude protein x 3.5 + % crude fat x 8.5 + %
NFE (Nitrogen-free extract) × 3.5). The correct dosage
was calculated using another expression 110 kcal ME*kg
bw0.75 (Nutritional Guidelines for Complete and Com-
plementary Pet Food for Cats and Dogs and Nutrient re-
quirements of dogs and cats, National research council
of the National accademies). The constant 110 is re-
ferred to the energy requested by a dog with normal
physical activity. At the enrollment, each animal was
weighed and the suggested daily ratio calculated. The
Veterinarians clearly informed the owners about the cor-
rect dosage to be provided. Moreover the average of
daily administered botanicals was calculated considering
the ratio given to the dogs, related to the amount de-
clared by the manufacturer. Table 3 highlights the aver-
age amount, in terms of mg/kg, of botanicals estimated
according to the mean weight.
Ophthalmologic examination
Each dog was evaluated on day 0,15, 30, and 60 of the
evaluation by an independent observer (SD, DG, CM).








score (0-3 ± SEM)
Conjunctival inflammation
score (0-3 ± SEM)
Mucus discharge
score (0-3 ± SEM)
Corneal keratinization
score (0-2 ± SEM)
Control 6.03 ± 0.15 13.04 ± 1.12 4.3 ± 0.5 1.0 ± 0.1 2.1 ± 0.1 1.7 ± 0.1 1.5 ± 0.1
Treatment 6.1 ± 0.17 12.01 ± 1.17 4.7 ± 0.4 0.9 ± 0.1 2.1 ± 0.1 1.8 ± 0.1 1.5 ± 0.1
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Each dog underwent a complete ophthalmological exam-
ination by three board-certified veterinary ophthalmolo-
gists (Dr. M.C. Muscolo and Dr. S. De Stefanis are
board-certified by the D’Ophtalmologie ENV Alfor; Dr.
D. Giretto is board-certified by Certificat d’Etudes
Superieur en Ophtalmologie ENV Toulouse and is an
Italian Animal Health Foundation board member).
Ophthalmic examinations included, slit-lamp biomi-
croscopy (Kowa Optimed Inc SL-14 Slit Lamp, Kowa
Optimed, Europe Ltd, Berkshire, UK), funduscopic exam-
ination (Heine Omega 180 Binocular Indirect Ophthalmo-
scope, HEINE Optotechnik, Herrsching, Germany),
applanation tonometry (Tono-Pen® Vet, Reichert Tech-
nologies, Depew, NY, USA) preceded by an ocular applica-
tion of oxybuprocaine hydrochloride 0.4% (Novesina
Novartis Farma S.p.A, Origgio (VA), Italy) in order to re-
duce the nuisanceand fluorescein dye staining (fluorescein
0.5% collyre unidose TVM, Laboratoires TVM, Lempdes,
France) along with 0.9% physiologic rinsing solution
(Eurospital S.p.A., Trieste, Italy).
Both eyes of each dog were photographed at each visit
in the afternoon (3–6 pm) and clinical signs, such as
corneal pigment density and corneal keratinization, were
graded according to the scores proposed by Hendrix et
al. [93], whereas conjunctival inflammation and mucus
discharge were graded according to the scores proposed
by Moore et al. [94].
– corneal pigment density (0-3): 0 = no pigment, 1 =
iris easily visualized through the pigment, 2 = iris
partially visualized through the pigment, 3 = iris not
visible through the pigment);
– conjunctival inflammation (0-3): 0 = normal
conjunctiva; 1 = mild hyperemia without chemosis;
2 = moderate hyperemia with mild chemosis; 3 =
intense hyperemia with moderate to severe chemosis;
– mucus discharge (0 – 3): 0 = no visible mucus or
clear mucus thread; 1 = scattered non-adherent
mucopurulent strands; 2 = moderate adherent
mucopurulent strands covering up to 25% of
the cornea; and 3 = diffuse extensive adherent
mucopurulent discharge covering 25% to 50%
of the cornea;
– corneal keratinization (0-2): 0 = none, 1 = mild
opacity, 2 = moderate opacity.
Enrolled dogs were treated by their owners at home by
applying the pharmacological treatment as previously
described and the diet administration approximately
every 12 h.
Schirmer tear test
Schirmer tear test-1 (STT-1) is a routine examination
which is performed by placing a standard test strip
(Schirmer-Plus®, Gecis Ecoparc, Domaine de Villemor-
ant, France) within the ventral conjunctival sac of each
dog for 60 s. Tear production is then recorded in mm/
min for each eye. STT-1 was performed on 100 eyes of
dogs of several breeds.
Statistical analysis
Data were analyzed using GraphPad Prism 6 software
(GraphPad Software, Inc., La Jolla, CA, USA). All data are
presented as the means ± standard error of the mean and
were first checked for normality using the D’Agostino-
Pearson normality test. Differences in Schirmer test,
conjunctival inflammation, corneal keratinization, corneal
pigmentation density and mucus discharge score between
Table 2 Daily table recommendation for diet
Weight (Kg) Diet amount per day (g)
1 – 10 30 – 180
11 – 20 190 – 300
21 – 35 310 – 455
36 – 50 465 – 595
Table 3 Average substances administer to dog depending on body weight (considering medium body weight)
Nutraceutical substances Amount per kg of complete food Dog weight 10 kg 11 kg 12 kg 13 kg
Ascophyllum nodosum 40000 mg/kg 7200 7600 8200 8600
Cucumis melo 300 mg/kg 54 57 61,5 64,5
Carica papaya 135 mg/kg 24,3 25,65 27,675 29,025
Aloe vera 135 mg/kg 24,3 25,65 27,675 29,025
Haematococcus pluvialis (astaxanthin) 49 mg/kg 8,82 9,31 10,045 10,535
Resveratrol (Poligonum Cuspidatum) 7 mg/kg 1,26 1,33 1,435 1,505
Zinc sulphate monohydrate 137 mg/kg 24,66 26,03 28,085 29,455
Curcuma longa 102 mg/kg 18,36 19,38 20,91 21,93
Camellia sinensis 70 mg/kg 12,6 13,3 14,35 15,05
Punica granatum 70 mg/kg 12,6 13,3 14,35 15,05
Piper nigrum 30 mg/kg 5,4 5,7 6,15 6,45
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the two treatments at the end of treatment versus baseline
for each eye were blindly analyzed by ADC using a two-
way analysis of variance (ANOVA) followed by Sidak’s
multiple comparisons test. Conjunctival inflammation,
corneal keratinization, corneal pigmentation density and
mucus discharge score between the two treatments at the
end of treatment versus baseline for each eye were ana-
lyzed using a paired t-test. Veterinary ophthalmologists
were not involved in the statistical analysis of the data.
Results and Discussion
Clinical evaluation of eyes in ND and SD group
Fifty dogs were enrolled in the trial: 25 dogs received the
pharmacological treatment and a standard diet (SD Group),
while 25 dogs received the pharmacological treatment
plus an antioxidant/anti-inflammatory nutraceutical diet
(ND Group).
An overall amount of 100 eyes was considered accord-
ing to literature suggestions [95–97]. All dogs completed
the 60-day evaluation period.
The overall improvement of eye’s condition in two repre-
sentative dogs of ND group at the day 0 of the trial (Fig. 1a,
c) and at the end of the 60-days evaluation (Fig. 1b, d) is
shown. In particular, our results highlight the clinical ameli-
oration occurred in ND group (Fig. 1b, d) in terms of
blepharospasm, ocular hyperemia, periocular swelling and
ocular discharge that is strongly dependent on nutraceuti-
cals administration since no effects were evident in SD
group (Fig. 1e, h). In this regard, the comparative evaluation
between the day 0 (Fig. 1e, g) and the end of 60-days (Fig. 1f,
h) in two representative dogs of SD group showed none
significant clinical amelioration. Indeed, blepharospasm,
ocular hyperemia, periocular swelling and ocular discharge
were still evident or, at least, poorly improved.
These results strongly pointed to a specific effect of
nutraceuticals in inducing anti-inflammatory and immune-
modulating outcomes in eyes of dogs belonging to ND
group. Notably, the standard pharmacological treatment
appeared to be substantially ineffective since no amelior-
ation has been observed in dogs belonging to SD group.
Therefore, the effect of nutraceuticals could be considered
as highly fostering the clinical improvement during the
pharmacological treatment in cKCS.
The eye’s scores amelioration in cKCS dogs treated with ND
Figure 2 shows the eye’s score intensity trend of each
symptom of dogs belonging to SD and ND group.
Dogs conjunctival inflammation score significantly de-
creased from a baseline of 2.1 ± 0.1 to 0.6 ± 0.1 in the ND
group, while no significant variation (from a score of 2.1 ±
0.1 to 1.9 ± 0.1) appeared in SD group (Fig. 2a–b).
In addition, corneal keratinization score resulted
significantly decreased in ND group (from 1.5 ± 0.1 to
0.2 ± 0.1) and not in SD group (from 1.5 ± 0.1 to 1.4 ± 0.1)
(Fig. 2c–d). Finally, corneal pigment density and mucus
discharge resulted significantly decreased only in ND
group, while no effects were evident in SD group.
More in details, corneal pigment density scores de-
creased from a baseline value of 0.9 ± 0.1 to 0.2 ± 0.1
whereas mucus discharge scores decreased from 1.8 ±
0.1 to 0.3 ± 0.1 (Fig. 2e–h).
These results clearly suggest the role for ND in indu-
cing the amelioration of eye’s score testing in cKCS and
that this occurrence appears independent on pharmaco-
logical treatment since drugs alone appeared ineffective,
as evident in SD group.
As to STT-1 values, a significant increase was observed
from a baseline value from 4.7 ± 0.4 mm to 10.7 ± 0.6 mm
after the 60-days of treatment only in the dogs of ND
group, while no significant improvement (STT-1 values
from 4.3 ± 0.5 mm to 5.1 ± 0.5 mm) was evident in the
dogs of SD Group at the end of the trial (Fig. 2i–l).
Fig. 1 Eyes improvement after 60-days treatment with 0,03%
Tacrolimus collyrium BID and 0,2% Hyalistil eyewash plus the
nutraceutical diet in ND group and with with 0,03% Tacrolimus
collyrium BID and 0,2% Hyalistil eyewash plus the standard diet
in SD group. a–c eye before treatment plus nutraceutical diet (time = 0),
b–d eye at the end of treatment plus nutraceutical diet (time = 60). e–g
eye before treatment plus standard diet (time = 0), f–h eye at the end
of treatment plus standard diet (time = 60)
Destefanis et al. BMC Veterinary Research  (2016) 12:214 Page 6 of 12
These results evidenced the effectiveness of ND in in-
crease the tear film in our cohort of sick dogs. It is reason-
able that the anti-inflammatory effects of nutraceuticals
could contribute to restore the physiological eye’s tear
production in cKCS.
The relapse/regression of cKCS symptoms in dependence
of ND administration
After the 60 days of evaluation, dogs belonging to
ND group interrupted the diet supplementation for
30 days, while continuing the pharmacological treatment.
Fig. 2 a mean tear production (STT) in mm/min before and after 60 days treatment for ND and SD group, STT values resulted significantly
increased (****P < 0.0001) in ND group at the end of treatment, b Mean conjunctival inflammation scores before and after 60 days treatment for
ND and SD group, a significant decrease (****P < 0.0001) was observed in ND group at the end of the treatment; c mean corneal keratinization
scores before and after 60 days treatment for ND and SD group, a significant decrease (****P < 0.0001) was observed in ND group at the end of
the treatment; d mean corneal pigment density scores before and after 60 days treatment for ND and SD group, a significant decrease (****P <
0.0001) was observed in ND group at the end of the treatment; e mean mucus discharge scores before and after 60 days treatment for ND and
SD group, a significant decrease (****P < 0.0001) was observed in ND group at the end of the treatment
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It is worth noting that a rapid and intensive relapse
of symptoms was observed after 15 days since ND
suspension. All dogs were newly supplemented with
the ND while continuing the pharmacological therapy
for another 30 days. Intriguingly, an overall regression
of symptoms was again observed after the reintroduc-
tion of ND (Fig. 3).
This occurrence clearly highlighted the specific ef-
fects of nutraceuticals as useful adjuvant in the treat-
ment of cKCS-affected dogs, particularly for those
animals poorly responsive or unresponsive to standard
pharmacological therapy.
Conclusions
To the best of our knowledge, this clinical evaluation
represents first study that proposed the use of a specific
antioxidant/anti-inflammatory ND as an optimal com-
bination of ingredients with synergistic effects able to
potentially exert an immune-modulating activity in com-
bination with standard pharmacological treatments in
cKCS.
The nutraceutical approach appears to significantly in-
crease the eye’s tear production and to clinically amelior-
ate the conjunctival inflammation status as well as the
corneal keratinization, corneal pigment density and
mucus discharge in chronic cKCS dogs poorly responsive
or unresponsive to immune-suppressive therapy.
The increased STT level in response to the proposed
ND was in agreement with previously reported response
to topical CsA and Tacrolimus [23, 98, 99]. Although we
are unaware of the possible action mechanism of all in-
gredients, in particular for the phytotherapic extracts,
we hypothesize that these substances and raw materials
of the ND may exert a synergic action in the T-cell
activation, possibly by preventing inflammatory gene
transcription (IL-2, IL-3, IL-4, IFN- γ, TNF-α, GM-CSF,
c-myc) [16, 100, 101].
Fig. 3 Graphical schematization of clinical symptoms score trends
after 30 days since treatment suspension and after 30 days since
treatment resumption. a Mean conjunctival inflammation scores
before (T 60) and after 30 days nutraceutical diet suspension (T 90)
for ND group and (b) after 30 days since nutraceutical diet resumption
(T 120); c mean corneal keratinization scores before (T 60) and after
30 days nutraceutical diet suspension (T 90) for ND group and (d) after
30 days since nutraceutical diet resumption (T 120); e mean corneal
pigment density scores before (T 60) and after 30 days nutraceutical
diet suspension (T 90) for ND group and (f) after 30 days since
nutraceutical diet resumption (T 120), scores resulted significantly
increased (*P < 0.05); g mean mucus discharge scores before (T 60)
and after 30 days nutraceutical diet suspension (T 90) for ND group
and (h) after 30 days since nutraceutical diet resumption (T 120), scores
resulted significantly increased (**P < 0.01); i mean tear production
(STT) in mm/min before (T 60) and after 30 days nutraceutical diet
suspension (T 90) for ND group and (l) after 30 days since nutraceutical
diet resumption (T 120)
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Based on a possible mimicking action mechanism of all
active substances with respect to CsA, we also hypothe-
sized a reduced secretion of TNF-α by T cells. In this
regard, TNF-α is known to increase mucin secretion from
respiratory epithelial cells, thus it could possibly influen-
cing the mucus production, corneal keratinization and
conjunctival inflammation status [102, 103]. However, as
observed by Hendrix et al. an overall significant improve-
ment of clinical signs was not observed over time [93].
Intriguingly, our results seem to support the use of an
anti-inflammatory/immune-modulating ND as an adju-
vant to drug therapy in those cKCS dogs unresponsive to
pharmacological treatment, in order to achieve analogue
results of the responsive subjects (Moore et al., [94],
Hendrix et al., [93]). Therefore, our investigation high-
lights the relevance of the possible administration of anti-
oxidant/anti-inflammatory nutraceutical diet to cKCS
dogs as useful adjuvant of immunosuppressive therapy.
The combination of a pharmacological treatment with
a specific diet (Ocu-GLO Rx™) was also recently assessed
by Williams et al. who successfully delayed the cataract
formation in dogs with diabetes mellitus [104]. Specific-
ally, the diet consisted in a mixture of a aldose reduc-
tase inhibitor, a glutathione regenerator alpha lipoic
acid, grape seed extract, carotenoids, omega-3-fatty
acids, and coenzyme Q10 which was provided to dia-
betic dogs as far as these developed lens opacification.
Mean time without change in lens opacification was
278 ± 184 days with Ocu-GLO Rx™ and 77 ± 40 days in
the placebo group.
In our treatement approach, the combination of sev-
eral nutraceuticals, such as fish hydrolised proteins, rice
carbohydrates, Cucumis melo, Ascophyllum nodosum,
Astaxanthin, Aloe vera, Carica papaya, Punica grana-
tum, Camellia sinensis, Polygonum L., Curcuma longa,
Piper nigrum, zinc and a omega3/6 polyunsaturated fatty
acids (1:0.8 ratio), appears to exert beneficial immune-
modulating effects on the clinical status of cKCS dogs.
These data seams to confirm the action of nutraceutical
diet on immune system modulation reducing Th1 and
inproving TReg [35].
These plants and substances, widely used in trad-
itional medicine, have been already shown to exert
some intriguing antioxidant and anti-inflammatory ac-
tivities in ocular tissues. In this regard, it is worth
noting that Camellia sinensis extract was effective in
conjunctival inflammation treatment [105] and Curcuma
longa in several ocular diseases (chronic anterior uveitis,
diabetic retinopathy, glaucoma, age-related macular
degeneration and dry eye syndrome) [106, 107]. In
addition, zinc was observed to reduce the progression
of the age-related macular degeneration by the inhib-
ition of the complement activation on retinal pigment
epithelium cells [108] and omega 3 -6 fatty acids were
closely correlated to development of vision and pro-
tection of eyes [109, 110].
The antioxidant/anti-inflammatory effects likely pos-
sessed by the mixture based on all these nutraceuticals
in the diet supplementation seems to specifically reduce
the immune-mediated ocular symptoms, particularly in
those cKCS dogs that were poor responsive or unre-
sponsive to classical immune-suppressive drugs.
In this regard, the pharmacological treatment alone
was able to increase lachrymal production, while the in-
crement was strongly higher and persistent when drugs
were combined with the ND. Likewise, conjunctival in-
flammation was significantly reduced more in dogs be-
longing to ND group (receiving drugs in combination
with nutraceutical supplemented diet) than in the SD
group (receiving only the medical treatments). In
addition, it is of relevance that corneal pigment density
and mucus discharge were improved only in dogs be-
longing to the ND group. Finally, the occurrence of
symptom relapsing, upon the suspension of nutraceutical
diet, and of clinical amelioration, after its reintroduction,
fosters the hypothesis of a possible therapeutical benefit
of this nutraceutical diet in animal as well as in human
ocular diseases [111, 112]
Taken in all, our results suggest that association of clas-
sical drug therapy with a nutraceutical diet with potential
antioxidant/antiinflammatory and immune-modulating
activities induce a significant amelioration of clinical signs
and symptoms in keratoconjunctivitis sicca. Moreover, all
symptoms appeared dependent on immune-mediated
mechanisms. In this regard, the lachrymation impairment
can be altered by an inflammatory condition of lachrymal
gland and related ducts.
Therefore, it is reasonable to hypothesize that meta-
bolic changes could affect immune response orchestra-
tion in a model of immune-mediated ocular disease,
as represented by keratoconjunctivitis sicca, in dogs
and, in a translational perspective, by Sjögren’s syn-
drome in humans.
Study limitations
This research has some study limitations. For instance,
neither the inflammatory cytokines present in the serum
of dogs affected by KCS nor the percentage of regulatory
T cells in the blood were evaluated. Ongoing experi-
ments are characterizing the inflammatory cytokine re-
lease as well as the presence of Treg cells in peripheral
blood. Moreover, preliminary results have evidenced that
it is really hard to find in blood those alterations likely
present in a well-defined peripheral tissue and body district,
as represented by the eye.
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